Author: digi

Metrics for Evaluating Site Performance Across Past Trials

September 8, 2025

Metrics for Evaluating Site Performance Across Past Trials Key Metrics for Evaluating Clinical Site Performance Across Historical Trials Introduction: Why Historical Metrics Drive Better Site Selection In an increasingly complex regulatory and operational environment, sponsors and CROs are under pressure to select clinical trial sites that can deliver quality data, timely enrollment, and regulatory compliance….

Historical Performance Review, Study Feasibility and Site Selection

Sponsor and Site Roles During Regulatory Inspections

September 8, 2025

digi

Sponsor and Site Roles During Regulatory Inspections Understanding Sponsor and Site Responsibilities During Inspections Shared Accountability in Regulatory Inspections Regulatory inspections, whether routine or for-cause, assess the integrity, conduct, and regulatory compliance of clinical trials. Both sponsors and clinical sites play critical and often overlapping roles during these inspections. Agencies such as the FDA, EMA,…

Audit Trails and Inspection Readiness, Regulatory Inspection Types (Routine, For-Cause)

Safety Department Readiness for Expedited SAE Reports

September 8, 2025

digi

Safety Department Readiness for Expedited SAE Reports Preparing Safety Departments for Expedited SAE Reporting in Clinical Trials Why Safety Department Readiness Is Essential The safety department, often referred to as the pharmacovigilance (PV) unit, plays a pivotal role in ensuring that Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) are reported within…

Adverse Event Reporting and Management, Expedited Reporting Timelines

SOP for Clinical Trial Monitoring and Oversight

September 8, 2025

digi

SOP for Clinical Trial Monitoring and Oversight { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.clinicalstudies.in/clinical-trial-monitoring-and-oversight” }, “@id”: “https://www.clinicalstudies.in/clinical-trial-monitoring-and-oversight”, “headline”: “SOP for Clinical Trial Monitoring and Oversight”, “name”: “SOP for Clinical Trial Monitoring and Oversight”, “description”: “Comprehensive SOP describing sponsor, investigator, and monitor responsibilities for clinical trial monitoring and oversight in New Zealand,…

Medsafe/HDEC — Unique SOPs (New Zealand), SOP for GCP

How to Prepare for Audits Involving Remote SDR and Centralized Review

September 8, 2025

digi

How to Prepare for Audits Involving Remote SDR and Centralized Review Audit Preparation Guide for Remote SDR and Centralized Monitoring Activities Why Auditors Are Increasingly Focusing on Remote SDR Remote Source Data Review (SDR) has become a key strategy for maintaining clinical trial oversight in decentralized and hybrid models. While effective, it introduces new regulatory…

Remote Monitoring and Virtual Visits, Source Data Review Remotely

SOP for Remote/Central Monitoring Procedures

September 8, 2025

digi

SOP for Remote/Central Monitoring Procedures { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.Clinicalstudies.in/SOP-for-Remote-Central-Monitoring-Procedures” }, “headline”: “SOP for Remote and Central Monitoring Procedures in Clinical Trials”, “description”: “This SOP outlines standardized processes for conducting remote and central monitoring in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP guidance while…

Global SOPs (Applicable to all Agencies), SOP for GCP

Retention Requirements for Deviation Documentation

September 8, 2025

digi

Retention Requirements for Deviation Documentation Retention Guidelines for Deviation Documentation in Clinical Research Why Deviation Documentation Must Be Retained Protocol deviations are critical records in clinical trials, providing evidence of trial conduct, subject protection, and regulatory compliance. Retaining deviation documentation is not optional—it is a core expectation under ICH-GCP, FDA, EMA, and other regional guidelines….

Deviation Logs and Tracking Tools, Protocol Deviation and CAPA Management

Cultural Sensitivity in Global Trial Design

September 8, 2025

digi

Cultural Sensitivity in Global Trial Design Designing Clinical Trials with Cultural Sensitivity in Global Research Introduction: Why Cultural Sensitivity Matters Global clinical trials are critical for generating diverse data on safety and efficacy. However, cultural differences can create ethical, operational, and trust-related challenges. Issues such as informed consent, gender dynamics, community beliefs, and healthcare-seeking behaviors…

Clinical Trial Transparency and Ethics, Ethical Dilemmas in Global Research

IRB Training and Oversight Deficiencies Highlighted in Audits

September 8, 2025

digi

IRB Training and Oversight Deficiencies Highlighted in Audits Why IRB Training and Oversight Deficiencies Are Highlighted in Audits Introduction: The Importance of IRB Training and Oversight Institutional Review Boards (IRBs) or Ethics Committees (ECs) are entrusted with ensuring that clinical trials adhere to ethical principles and regulatory standards. For IRBs to perform effectively, members must…

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Documenting and Verifying Training Effectiveness at CROs

September 8, 2025

digi

Documenting and Verifying Training Effectiveness at CROs Ensuring Proper Documentation and Verification of Training at CROs Introduction: Why Training Documentation Matters Training is one of the most scrutinized areas during regulatory inspections and sponsor audits of Contract Research Organizations (CROs). While general GCP training establishes the foundation, it is the documentation and verification of study-specific…

CRO Audits, CAPA, and Deviation Management, Training & Quality Culture in CROs